Markets

Baron Funds Comments on Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company ( NYSE:BMY ) is a large diversified pharmaceutical company that is one of the leaders in the development of immune-system-stimulating therapies to fight cancer. These efforts are spearheaded by its product Opdivo, now approved to treat several types of cancer. After positive data was released on a rival drug to treat first-line advanced non-small-cell lung cancer, Bristol-Myers revealed that Opdivo did not meet the primary endpoint in a Phase III trial in the same indication, and its shares fell. We have exited our Bristol-Myers position, but are continuing to research the budding immuno-oncology space carefully. (Josh Riegelhaupt)

From Baron Opportunity Fund third-quarter -…-6 commentary .

Read More:

About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .

This article first appeared on GuruFocus .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BMY

Other Topics

Stocks

Latest Markets Videos